MX2022004283A - Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo. - Google Patents

Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.

Info

Publication number
MX2022004283A
MX2022004283A MX2022004283A MX2022004283A MX2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A
Authority
MX
Mexico
Prior art keywords
yrimidin
enenitrile
oxetan
pent
pyrazolo
Prior art date
Application number
MX2022004283A
Other languages
English (en)
Inventor
Ann Neale
Dolca Thomas
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022004283A publication Critical patent/MX2022004283A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En la presente memoria se describen métodos para tratar pénfigo en un paciente humano que lo necesita que comprenden administrar al paciente humano una dosis de al menos 400 mg de (R)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo (PRN1008) una vez al día (QD) o dos veces al día (BID).
MX2022004283A 2019-10-09 2020-10-08 Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo. MX2022004283A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913029P 2019-10-09 2019-10-09
US201962942877P 2019-12-03 2019-12-03
PCT/US2020/054809 WO2021072095A1 (en) 2019-10-09 2020-10-08 Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Publications (1)

Publication Number Publication Date
MX2022004283A true MX2022004283A (es) 2022-07-12

Family

ID=73030241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004283A MX2022004283A (es) 2019-10-09 2020-10-08 Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.

Country Status (13)

Country Link
US (2) US20210106583A1 (es)
EP (1) EP4041240A1 (es)
JP (1) JP2022552199A (es)
KR (1) KR20220079909A (es)
CN (1) CN115190798A (es)
AU (1) AU2020363873A1 (es)
BR (1) BR112022005575A2 (es)
CA (1) CA3153750A1 (es)
CO (1) CO2022005949A2 (es)
IL (1) IL291726A (es)
MX (1) MX2022004283A (es)
TW (1) TW202128172A (es)
WO (1) WO2021072095A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
EP3107544B1 (en) 2014-02-21 2020-10-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
MA41256B1 (fr) 2014-12-24 2021-02-26 Principia Biopharma Inc Dosage spécifique de site d'un inhibiteur de btk
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2019208805A1 (ja) * 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤

Also Published As

Publication number Publication date
US20230158033A1 (en) 2023-05-25
CO2022005949A2 (es) 2022-07-29
EP4041240A1 (en) 2022-08-17
US20210106583A1 (en) 2021-04-15
TW202128172A (zh) 2021-08-01
CN115190798A (zh) 2022-10-14
IL291726A (en) 2022-05-01
KR20220079909A (ko) 2022-06-14
BR112022005575A2 (pt) 2022-06-21
WO2021072095A1 (en) 2021-04-15
JP2022552199A (ja) 2022-12-15
CA3153750A1 (en) 2021-04-15
AU2020363873A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
MY194911A (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2021002380A (es) Conjugados de isoquinolina-esteroide y usos de los mismos.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
EP4233913A3 (en) Improved bromocriptine formulations
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
Besse et al. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2022001535A (es) Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
TW200719893A (en) Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
MX2022004283A (es) Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.